Previous 10 | Next 10 |
2024-04-03 10:00:34 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 99.9% to $0.2007 on volume of 121,318,217 shares Next.e.GO N.V. (EGOX) rose 30.8% to $0.034 on volume of 63,981,361 shares C3is Inc. (CISS) rose 20.8% to $0.0494 on volume of 63,446,681 shares I...
2024-04-03 07:51:20 ET More on ARCA biopharma Financial information for ARCA biopharma Read the full article on Seeking Alpha For further details see: ARCA biopharma to merge with Oruka Therapeutics in all-stock transaction
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and...
ARCA biopharma Inc. (ABIO) is expected to report for Q4 2023
2024-02-01 16:38:32 ET More on ARCA biopharma Financial information for ARCA biopharma Read the full article on Seeking Alpha For further details see: ARCA biopharma GAAP EPS of -$0.37
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applyi...
2023-07-21 16:30:29 ET ARCA biopharma press release ( NASDAQ: ABIO ): Q2 GAAP EPS of -$0.10. Cash and cash equivalents were $40.2 million as of June 30, 2023, compared to $42.4 million as of December 31, 2022. ARCA believes that its current cash and cash equivalents, c...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a...
News, Short Squeeze, Breakout and More Instantly...
ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25,...
ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company app...
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...